Abstract: Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor prognosis and limited therapeutic options. Identification of patients who will respond to HMAs is challenging. Mechanisms underlying resistance to HMAs are not clear yet. Recently, absence of response has been associated with increased cell-cycle quiescence among the hematopoietic progenitor cells. There are no standard-of-care options for patients after HMA failure. However, the increasing knowledge of MDS pathogenesis has led to the development of new potential therapies, including HMAs with longer half-life and exposure, inhibition of the antiapoptotic BCL2 protein with venetoclax or inhibition of immune-checkpoint regulatory proteins such as PD-1 or CTLA-4, innate immunity and targeting of CD33/CD3 with multiple monoclonal antibodies. In addition, multiple targeted agents are opening opportunities to treat subgroups of patients whose disease harbors mutations in TP53, IDH, FLT3, and genes involved in splicing machinery. Newer formulations of intensive chemotherapy and its different combinations may be considered a valid option in selected patients after HMA failure. Finally, decision making at the time of failure of response to HMAs should be personalized, taking into account that allogenic stem-cell transplantation remains the only therapeutic approach with curative potential in these patients. In the current review, we will focus on all the above aspects.
Introduction
Myelodysplastic syndromes (MDS) are a very heterogeneous group of clonal disorders of the bonemarrow hematopoietic stem cells (HPSCs), characterized by ineffective hematopoiesis with peripheral blood cytopenias and a higher risk for developing acute myeloid leukemia (AML). 1 Several prognostic models such as the International Prognostic Scoring System (IPSS) and its revised version (IPSS-R) allow stratification of patients into risk categories based on the degree and number of their cytopenias, observed cytogenetic abnormalities, and bone-marrow blast percentage. 2 The standard of care for patients with higher-risk MDS is treatment with hypomethylating agents (HMAs) azacitidine (AZA) 3 and decitabine (DAC). 4 In addition, although therapy in lower-risk MDS has traditionally been directed toward treatment of cytopenias with growth-factor support or lenalidomide in the setting of del(5q) MDS, HMAs have been shown as effective in lower-risk disease, with recent studies suggesting a role of early intervention using these agents. 5 Although therapy with these agents has been shown to prolong survival, only 40-50% of patients respond to therapy; responses are almost universally transient, with loss of response within 2 years. Once response to these agents is lost, the prognosis is very poor and the median overall survival (OS) is 4.3 and 14 months in high-and low-risk MDS, respectively. 6 In addition, there is significant heterogeneity in the nature of failure to HMA with a subset of patients experiencing progressive disease and transformation to acute myeloid leukemia, and another group of patients experiencing bone-marrow failure and progressive cytopenias. As a result of this, therapeutic needs and prognosis of these two groups of patients may likely differ. In fact, certain clinical biomarkers, such as age, performance status, complex cytogenetics (defined as >4 abnormalities), bone-marrow blast > 20%, platelet count and red cell transfusion dependency are potential predictors of outcome after failure of response to HMAs and can identify two subsets of patients with loweror higher-risk disease, with median OS of 11.0 versus 4.5 months, 7 respectively, from the time of failure.
As a result of this, development of new therapeutic strategies to prevent or overcome HMA failure is fundamental. This is particularly the case, since there are no standard-of-care options for patients with MDS who experience failure with HMAs. In this manuscript, we will review the mechanisms of failure to respond to HMAs, as well as the salvage therapeutic options for these patients.
Failure to respond to hypomethylating agents: definition and mechanisms
Primary response failure to respond to HMAs is considered in the absence of a response after at least four to six cycles of therapy, or when the MDS progresses to higher-risk categories or transforms to AML without having responded to therapy. 8 Secondary failure of response to HMAs is defined as the loss of response, progression to a higher-risk category or transformation to AML in a patient who had an initial response to therapy. Although some clinical parameters and genetic mutations have weak correlations with favorable HMA response, the molecular mechanisms underlying HMA resistance are poorly understood. 9, 10 Several efforts have been made to identify predictive biomarkers of response to HMAs. Although therapeutic decisions don't have to be based on molecular mutations alone, there are some molecular biomarkers associated with response to HMAs. TET2 mutations have been identified as predictive of response to AZA when present at >10% allele burden, particularly in the absence of ASXL1 mutations, without a clear knowledge of the mechanism. 11, 12 The expression of miR29b also has a role in the response to HMA. miR29b targets the deoxyribonucleic acid (DNA) methyltransferases (DNMTs), resulting in global DNA hypomethylation and re-expression of hypermethylated, silenced genes in AML. The overexpression of miR29b in myeloid blasts has been associated with clinical response to the hypomethylating effects of DAC. 13, 14 Different resistance mechanisms to HMAs have been described in literature. Since global DNA and gene-specific hypermethylation characterize MDS, the notion that hypomethylation is likely the main mechanism of action of HMAs has been traditionally accepted. However, it has been shown that there is little association between the degree of demethylation following hypomethylating treatment and hematologic response. 15 Any alterations in the transport and metabolism of HMAs might cause insufficient active forms and insufficient incorporation into DNA/RNA (ribonucleic acid), resulting in resistance. Cellular transport across membranes is crucial for uptake of HMAs and depends on the presence of human nucleoside transporters (hNTs). It was observed that the presence of hNT inhibitors protected against HMA cytotoxicity, thus suggesting the importance of hNTs in manifestation of toxicity and possible utility as a biomarker of clinical response. 16 Similarly, lower expression of genes involved in AZA metabolism, such as UCK1, may influence clinical response. UCK1 was determined in 57 patients with MDS who received AZA, seeing lower expression in patients without response to AZA (median 0.2 versus 0.49 for patients with response to AZA, p = 0.07), which was corroborated in vitro, where the silencing of UCK1 by siRNA led to blunted response to AZA. 17 In addition, mutations of UCK2 have been associated with resistance to AZA in AZAresistant cell lines. 18 In a recent study, primary AZA resistance was associated with cell-cycle quiescence of the hematopoietic stem-cell progenitors (HSPCs). 19 By performing RNA sequencing from bone-marrow CD34+ HSPCs of nonresponders, the authors could identify downregulation of cell-cycle-related genes and journals.sagepub.com/home/tah 3 this finding was consistent with flow-cytometry analysis in which CD34+ cells from nonresponders were markedly quiescent. In this study, HSPCs quiescence was described as mediated by integrin alfa-5 (ITGA5) signaling, and the blockade of this integrin signaling, in combination with AZA, improved the hematopoietic potential of these cells.
Upregulation of innate immunity signaling via Toll-like receptor (TLR) signaling and nuclearfactor kappa B (NF-κB) activation, 20,21 as well as of adaptive immunity molecules, such as immunecheckpoint regulators, 22 has been linked to failure of response to HMAs. Overexpression of TLR2 has been described in bone-marrow CD34+ cells from patients with MDS, particularly after failure of response to HMAs, and inhibits colony formation with inhibition of TLR2 signaling restoring colony-formation capacity. In addition, programmed cell-death 1 (PD-1) and programmed cell-death ligand 1 (PD-L1) expression in HSPCs is associated with apoptosis and ineffective hematopoiesis. As will be later discussed, targeting these processes may have therapeutic potential after failure of response to HMAs.
Finally, a recent study suggests two main groups of MDS subtypes may exist, based on the HSPC architecture; one defined by expansion of the common myeloid progenitors (CMPs), and another by expansion of the granulomonocytic progenitors (GMPs). In addition, resistance to HMAs may originate from different HSPC compartments in each of these subgroups and may be a result of distinct biological mechanisms. For instance, upregulation of genes involved in promotion of cell proliferation and survival, such as BCL2, can be observed in long-term hematopoietic stem cells of patients with CMP pattern and progressive disease at the time of failure, while upregulation of genes involved in tumor necrosis factor alpha (TNF-α) is observed in lymphoidprime multipotent progenitors of patients with GMP pattern. 23 However, most of the underlying mechanisms of resistance remain unclear and are likely associated with a diversity of biological processes and, as aforementioned, dependent on specific bonemarrow-cell populations. In order to overcome this resistance, multiple new agents are currently being developed. FT-2102 Targeting BCL2 BCL2-like 10 (BCL2L10) is an antiapoptotic member of the BCL2 family commonly overexpressed in hematologic malignancies, acquiring antiapoptotic and therapeutic resistance. A prospective study including MDS and AML patients, showed that the overexpression of BCL2L10 in the bone-marrow mononuclear cells was significantly associated with a lower response rate to HMAs and with a shorter OS. 42, 43 Venetoclax (VEN) is a potent and highly selective BCL2 inhibitor, with high oral bioavailability. Several studies have evaluated the activity of VEN alone or in combination with HMAs in MDS and AML patients. As a single agent for patients with relapsed or refractory (R/R) AML, VEN has demonstrated 19% of ORR in heavily pretreated patients. 44 The outcome of VEN combination regimens in R/R AML, MDS and blastic plasmocytoid dendritic-cell neoplasm were reported in a study that included 43 patients. 28 In combination with VEN, the majority of patients received either DAC (53%) or AZA (19%); even received by 21 patients (68%) who had already received HMAs as a prior salvage regimen. The ORR was 21%, including two patients who successfully proceeded to allogenic stem-cell transplantation (alloSCT). Median OS was 3 months, with prolonged cytopenias as the most common complication. 
Immune-checkpoint regulation
Immune-regulatory proteins such as CTLA-4 and PD-1/PD-L1 play an important role inhibiting the T-cell antitumor immune response. Patients previously treated with HMAs upregulate the inhibitory checkpoint PD1/PD-L1, by reduced methylation of the PD-1 promoter in leukemia cells. For this reason, the antileukemic effect of CD8 cytotoxic T lymphocytes is significantly decreased, potentially contributing to HMA resistance. 46 In addition, recent studies suggest that therapy with HMAs may lead to increased double-stranded RNA cytosolic sensing, upregulation of hypermethylated retrovirus genes and type I interferon responses, leading to apoptosis in melanoma. 47, 48 Although it is unknown whether this mechanism is shared in leukemia, it further supports the notion of combining HMAs with immune-checkpoint regulators and drugs targeting innate immunity signaling. As a result, multiple monoclonal antibodies against immune-checkpoint regulators are being tested in numerous clinical trials. Splicing machinery mutations. Mutations in the spliceosomal genes SRSF2, U2AF1, ZRSR2 and SF3B1 are the most common class of mutations in patients with MDS. These mutations are always heterozygous and are exclusive with one another, suggesting that cells may tolerate only a partial deviation from normal splicing activity. Accordingly, leukemias with spliceosomal gene mutations are preferentially susceptible to additional splicing perturbations. This explains why modulation of spliceosome machinery is a new therapeutic approach in MDS and AML patients harboring spliceosome mutations. E7107 is a spliceosome inhibitor that was used to treat Srsf2 P95H -mutant engineered mice, achieving a greater splicing inhibition and reduction in leukemic burden compared with Srsf2 wild type. 69 A phase I study of H3-B8800, a splicing modulator, is currently ongoing for patients with previously treated MDS, AML and CMML [ClinicalTrials.gov identifier: NCT02841540].
Targeting innate immunity
TLRs are a family of pattern-recognition receptors that play a pivotal role in the innate immunity, by the activation of NF-κB and the expression of multiple cytokines. TLR2 is overexpressed in the bone-marrow CD34+ cells of MDS patients, especially after HMA therapy, resulting in ineffective hematopoiesis and, ultimately, in hematopoietic malignancies. 70 Consequently, this innate immunity signaling pathway is a new potential target in MDS patients.
Tomaralimab (OPN-305).
Tomaralimab is a fully humanized antagonistic IgG4-κ monoclonal antibody that binds TLR2. In a phase I/II trial [ClinicalTrials.gov identifier: NCT02363491], 71, 72 tomaralimab was administered to 22 low-risk MDS patients, all of them heavily pretreated (>50% of patients had received ⩾4 previous therapies) and transfusion dependent. ORR was 50%; 6/22 (27%) patients achieved transfusion independence for two consecutive cycles and 5/22 (23%) patients achieved at least a 50% reduction in the need for transfusions. There were no doselimiting toxicities or development of antidrug antibodies. Interestingly, a trend to increased response was observed in patients with higher TLR2 expression, with no differences in response based on cytogenetic or mutational profile.
Multikinase inhibition: rigosertib
Rigosertib is a small-molecule inhibitor of cellular signaling which acts by binding to the Ras-binding domain of multiple kinases, including RAS, PI3K and PLK. These kinases control some cellular signaling pathways often activated in hematological malignancies. Through these interactions, these proteins result in inactivation, leading to mitotic arrest and apoptosis of tumor cells. 73 In a phase III trial, 74 patients with high-risk MDS after failure to respond to HMAs were randomized to rigosertib plus best supportive care (BSC) versus BSC. No patients had an overall CR or PR, but 27% patients in the rigosertib group and 17% in the BSC group achieved a confirmed best bone-marrow blast response of either bone-marrow CR or bone-marrow PR. In terms of hematological improvement, there were no differences between both groups. Median OS was 8.2 months in the rigosertib group and 5.9 months in the BSC group [HR 0.87 (95% CI 0.67-1.14); p = 0.33]. Median OS improved in favor of rigosertib among very high-risk MDS patients, and in patients with primary HMA failure (median OS 7.6 versus 3.2 months, and 8.6 versus 5.3 months, respectively).
Recently, results of a phase II study of the combination of rigosertib with AZA in 17 R/R MDS patients were published, with an ORR of 59%. 75 A randomized phase III trial of rigosertib [ClinicalTrials.gov identifier: NCT02562443] is under development in a high-risk MDS population to confirm the potential role of this agent in this group of patients.
Bispecific CD33/CD3 antibodies
The bispecific T-cell engaging antibodies with dual specificity are antibodies that bind both CD3 T-cell receptor and CD33, which is frequently expressed on the surface of AML blasts and leukemic stem cells. 76 This creates an immune synapse, initiating lysis of CD33-expressing cells by T cells, and inducing expansion, differentiation and proliferation of T cells. AMG330 and AMV564 are two novel, bivalent, bispecific CD33/CD3-targeted immunotherapies, that are being studied in phase I clinical trials in R/R AML patients [ClinicalTrials.gov identifiers: NCT02520427 and NCT03144245, respectively]. First results from the AMV564 trial have been recently reported, in 18 R/R AML patients. 77 Reduction in bone-marrow blasts, ranging from 13% to 91%, was observed in 12/18 (67%) patients, including a PR after cycle 1 in one patient, with no dose-limiting toxicity or treatment-related grade ⩾ 3 adverse events. An ongoing phase I study is evaluating its safety and activity in patients with intermediate or high-risk MDS [ClinicalTrials.gov identifier: NCT03516591].
Cytotoxic drugs and combinations.
Intensive chemotherapy and its different combinations may be considered a valid option in selected patients after HMA-treatment failure. However, due to the high toxicity of these regimens, it is important to identify which patients will benefit most from induction chemotherapy. Researchers in a study including 307 MDS patients after HMA failure, randomized patients to either classical induction chemotherapy with 7+3, intermediate-to highdose cytarabine (IDAC), or purine-nucleosideanalog (PNA) based (fludarabine, cladribine, clofarabine). 78 The ORR was 41%, 64%, and 34% with IDAC and PNA induction chemotherapy, respectively, without differences in the median OS between the three groups. Age > 65, adverse cytogenetics, and the use of non-IDACcontaining regimens, were identified as factors that significantly decreased response to these cytotoxic therapies. These results support the use of induction chemotherapy as a reasonable platform to treat MDS after HMA failure in younger patients with adequate organ function and performance status, and absence of higher-risk disease features. In addition to the conventional chemotherapy regimen, other lower-intensity combinations using clofarabine in combination with low-dose cytarabine and CPX-351 can be options for this population and a subset of elderly patients with HMA failure.
Clofarabine. Clofarabine is a second-generation nucleoside analog with potential role in HMA failure. Low-dose clofarabine was studied in combination with cytarabine in a large cohort of patients with higher-risk MDS after HMA failure. 79 Seventy MDS patients were included, of whom 82% had high-risk disease, 23% had therapy-related MDS, 56% had a previous response to HMAs, and 44% had primary refractory disease. ORR was 44%, with 19% CRs, and median OS was 10 months. Furthermore, 30% of the responders were able to proceed to alloSCT, 56% of whom achieved long-lasting remission. A previous response to HMAs did not affect the outcome of these patients; the presence of a complex karyotype, a platelet count < 30 × 10 9 /l and a poor performance status being the only independent factors associated with poor survival. Treatment was generally well tolerated but was associated with relatively high rates of fever and infections that required significant supportive care.
CPX-351.
A liposomal formulation of cytarabine: daunorubicin at a 5:1 molar ratio was recently approved by the FDA for secondary AML (sAML), and newly diagnosed therapy-related AML. A phase II randomized study compared CPX-351 versus 7+3. 80 sAML patients treated with CPX-351 improved ORR, EFS and OS. Subsequently, these results were confirmed in a phase III randomized study [ClinicalTrials.gov identifier: NCT0169608] including 309 newly diagnosed high-risk/sAML patients treated with the liposomal formulation. 81 In view of the apparent activity of this compound in AML with MDS-related changes and secondary AML, this opens the possibility of future studies using CPX-351 for patients with higher-risk disease after HMA failure.
How to treat patients with lower-risk MDS after failure to respond to HMAs:
Patients with lower-risk MDS who continue to exhibit features of low-risk disease at the time of response failure to HMAs, although classified as low risk by models such as IPSS and IPSS-R, have an OS of 12−14 months. In the absence of approved drugs, selecting adequate therapy remains a challenge. 82 Similar results were observed with sotatercept therapy, with 49% of HI-E in 74 patients. 83 Lenalidomide is another therapeutic option for patients with isolated anemia and no significant thrombocytopenia, even in the absence of del(5q) aberration. 84 The use of this agent in this subset of patients can induce HI-E in up to 12% patients, with a rate of progression to AML of 11% and median OS of 87 months. 85 Additionally, although associated with modest-and short-lasting responses, sequential therapy with an alternative hypomethylating agent can be considered.
AlloSCT remains the only therapeutic approach with curative potential in these patients. However, it is associated with significant toxicity and mortality, thus limiting the number of patients who can potentially benefit from this therapy. 10, 86 Moreover, patients who have failed HMAs have higher risk of relapse after alloSCT, and consequently, of death. 87 Among 125 MDS patients, the probability of relapse after alloSCT at 3 years was 56.6% for patients with failure to HMA compared with 34.2% among responders. 88 most available data of these combinations are restricted to previously untreated patients. Moreover, given the absence of data evaluating the use of venetoclax in high-risk MDS after response failure to HMAs, we can only recommend its use in the context of a clinical trial. In the absence of a clinical trial, as in low-risk disease, sequential use of another HMA can be considered but, as previously mentioned, the likelihood of achieving a significant and long-lasting response is low. For fit patients, lower doses of chemotherapy, including purine analogs such as cladribine or clofarabine in combination with low-dose cytarabine should be considered, particularly in the subset of patients with normal karyotype and in the presence of NPM1 mutations.
AlloSCT should always be considered in these patients. Current advances in transplant technology are allowing older patients to be considered as candidates for transplant, with early data suggesting transplant with alternative donors, such as haploidentical transplantation, may be feasible, particularly in the context of clinical trials. 89, 90 In addition, recent studies suggest reduced-intensity conditioning may be able to achieve similar relapse-free survival (RFS) and OS in patients with MDS, 91 and that comorbidity and disease-risk indices may be more relevant in outcomes than chronological age. 92 In a study evaluating survival of 270 higher-risk MDS patients, median OS of the alloSCT patients was 19 months. 93 Of these patients, 38% went to transplant with progressive disease after HMA failure, and 38% with stable disease, with median OS of 17 months, and not reached, respectively. Moreover, the median OS of the higher-risk MDS patients who underwent alloSCT, including the ones with progressive disease, was significantly superior to the ones that received BSC, low-dose chemotherapy, intensive chemotherapy, or investigational therapies (median OS of 4, 7.3, 8.9, and 13 months, respectively).
Recently, somatic mutations in patients with MDS at the time of transplantation have been linked to survival outcomes. 94 ASXL1, RUNX1, and TP53 mutations are associated with shorter survival and shorter time to relapse after alloSCT, with TP53 mutations being particularly adverse. RAS pathway mutations at the time of transplantation have significantly elevated risk of early relapse, which may be overcome with myeloablative conditioning. Also, JAK2 mutations are associated with a higher rate of death without relapse, regardless of conditioning intensity. 95 Studying somatic mutations may provide information about the outcomes in patients with MDS who are going to receive alloSCT, improving decision making. In addition, a recent study also suggests mutation clonal burden prior to transplant may also influence outcomes. 96 The use of next-generation targeting sequencing, may help identify subgroups of patients who will derive the most benefit from particular conditioning regimens.
In order to try to reduce disease recurrence after transplantation, current data support the concept of post-transplant maintenance regimens, especially in patients with high-risk features. The dual activity of AZA as an antileukemic agent and inhibitor of graft versus host disease (GVHD) makes it a promising agent for post-transplant therapy. 97, 98 The first prospective multicenter trial using AZA as salvage therapy for relapse of myeloid malignancies after alloSCT included 30 patients, in whom an ORR of 47% achieved, with 23% CRs with severity of GVHD, as well as somewhat mild toxicities. 99 A median of three courses of AZA were administered, and 73% also received donor lymphocyte infusions. Moreover, it has been shown that this treatment is particularly valuable in patients with low disease burden and in MDS patients rather than AML. 97, 100 Recently, results from a study of 187 patients comparing low dose of AZA maintenance versus observation were presented. Although less than 30% of the AZA patients completed the planned 12 cycles, the study showed a trend toward improvement in RFS in the patients receiving more AZA cycles. 101 Maintenance with CC-486, a novel oral AZA formulation that allows extended dosing and prolonged activity, has also been explored, although with limited data on frequency of prior therapy with HMAs. 98 Thirty patients in CR after alloSCT received CC-486 once daily for 7 or 14 days in a 28-day cycle for up to 12 cycles and among these, 9 had received AZA prior to transplant. Median OS was not reached at a median follow up of 19 months, and estimated 1-year survival rates were above 80%. The incidence of chronic GVHD was 10%, and only two patients discontinued the study due to a GVHD event.
Therefore, HMAs may be an important new therapy in selected patients after alloSCT, but when to initiate therapy after transplant, and how long to continue it, are still unclear aspects of this approach. In addition, future studies will have to determine whether use of these agents will benefit patients who underwent alloSCT after failure of response to HMAs and if the addition of other targeted agents may improve post-transplant outcomes in patients with MDS. 
